Forum Pharming NL0010391025

quote:

Grumpy-XL schreef op 6 februari 2026 07:09:

www.prnewswire.com/news-releases/inve...

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Pharming and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 1, 2026, Pharming issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." The press release said that "[t]he FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric doses and confirm that children in the lower weight dose groups can achieve exposure levels comparable to the approved adult and adolescent regimen. The letter also identified an issue with one of the analytical methods used for production batch testing, and the FDA requested additional data and clarification on this point."

On this news, Pharming's American Depositary Receipt ("ADR") price fell $3.495 per ADR, or 17.07%, to close at $16.975 per ADR on February 2, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.co
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

quote:

Janssen&Janssen schreef op 6 februari 2026 07:30:

[...]

Alsof de gifbeker nog niet helemaal leeg is voor pharming. Maar ik snap de claim helaas wel.

quote:

Janssen&Janssen schreef op 6 februari 2026 07:30:

[...]

Alsof de gifbeker nog niet helemaal leeg is voor pharming. Maar ik snap de claim helaas wel.

quote:

Grumpy-XL schreef op 6 februari 2026 07:09:

www.prnewswire.com/news-releases/inve...

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Pharming and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 1, 2026, Pharming issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." The press release said that "[t]he FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric doses and confirm that children in the lower weight dose groups can achieve exposure levels comparable to the approved adult and adolescent regimen. The letter also identified an issue with one of the analytical methods used for production batch testing, and the FDA requested additional data and clarification on this point."

On this news, Pharming's American Depositary Receipt ("ADR") price fell $3.495 per ADR, or 17.07%, to close at $16.975 per ADR on February 2, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.co
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

• Er staat niet wat Pharming of het management precies verkeerd heeft gedaan. Het enige wat er staat is dat Pharming nieuws naar buiten heeft gebracht.

• Je kan op deze manier bij elk bedrijf een claim starten waarvan de koers als gevolg van een nieuwsbericht sterk daalt

• Ze richten zich op de houders van ADR’s die op de Nasdaq verhandeld worden. Er zijn echter nauwelijks ADR’s in omloop

quote:

Long1985 schreef op 5 februari 2026 23:22:

[...]

Als je naar de huidige markt kijkt, ligt Pharming nadrukkelijk op de radar als overnamekandidaat, ook zonder concrete geruchten. Het bedrijf opereert in het uiterst aantrekkelijke segment van zeldzame ziekten, waar grote farmaceuten actief zoeken naar schaalbare, winstgevende toevoegingen.

Ruconest blijft omzetmatig doorgroeien, en tijdens de Investor Day gaf de CEO expliciet aan dat eerder weggelopen patiënten zijn teruggekeerd. Dat onderstreept de kracht van het product en bevestigt dat de kasstroom structureel is, niet tijdelijk.

Met bewezen commerciële producten, een valide groeipijplijn en een achterblijvende waardering is Pharming geen speculatieve gok, maar een strategische buitenkans. Voor een grotere farmaceut is dit een snelle, relatief risicoloze manier om direct relevant te worden in rare diseases — en precies dát soort kansen wordt uiteindelijk opgepakt.

quote:

T. Edison schreef op 6 februari 2026 06:31:

[...]Bijzonder koersdoel.
Het klopt inderdaad dat er ongeveer 700 miljoen aandelen uitstaan. Op zich is dat geen probleem, daar is de koers van € 1,40 ook naar (als het er 70 miljoen zouden zijn zou de koers nu €14,00 zijn, maar zou iedereen er 9% minder bezitten met dezelfde investering)
Er zijn vele bedrijven die meer aandelen hebben uitstaan

Koersdoelen betreffen meestal een tijdspanne van een jaar.
Kunt u uitleggen waarom een bedrijf, waar iedereen zich inzet om goede bedrijfsresultaten neerr te zetten, in grootte zal halveren terwijl de omzetverwachting 2026 zo'n 10% hogere wordt gesteld dat die van 2025?
Deze laatste viel overigens al hoger uit dan waar begin 2025 op was gerekend, wat eerder een teken is van groei i.p.v. krimp.

quote:

Beur schreef op 6 februari 2026 08:50:

[...]Misleidende suggestie.
Chouraqui sprak wat betreft terugkeren van patiënten naar Ruc over "horen zeggen" en over niet meer dan "anecdotisch bewijs".

quote:

antop schreef op 6 februari 2026 08:56:

Mijn favoriete quote van Warren Buffett: ‘Wees bang als anderen hebberig zijn en hebberig als anderen bang zijn!’”

quote:

Grumpy-XL schreef op 6 februari 2026 07:09:

www.prnewswire.com/news-releases/inve...

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Pharming and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 1, 2026, Pharming issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." The press release said that "[t]he FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric doses and confirm that children in the lower weight dose groups can achieve exposure levels comparable to the approved adult and adolescent regimen. The letter also identified an issue with one of the analytical methods used for production batch testing, and the FDA requested additional data and clarification on this point."

On this news, Pharming's American Depositary Receipt ("ADR") price fell $3.495 per ADR, or 17.07%, to close at $16.975 per ADR on February 2, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.co
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

quote:

Long1985 schreef op 6 februari 2026 08:56:

[...]

We've also actually heard anecdotal evidence of some of those patients coming back to RUCONEST. However, we haven't seen any significant change in the bulk of the patients who are on RUCONEST.

Er zijn enkele patiënten die eerst zijn weggegaan en weer zijn teruggekomen naar RUCONEST (anekdotisch bewijs).

quote:

antop schreef op 6 februari 2026 08:56:

Mijn favoriete quote van Warren Buffett: ‘Wees bang als anderen hebberig zijn en hebberig als anderen bang zijn!’”

quote:

Long1985 schreef op 6 februari 2026 08:56:

[...]

We've also actually heard anecdotal evidence of some of those patients coming back to RUCONEST. However, we haven't seen any significant change in the bulk of the patients who are on RUCONEST.

Er zijn enkele patiënten die eerst zijn weggegaan en weer zijn teruggekomen naar RUCONEST (anekdotisch bewijs).